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Abstract
with the current standard of care for the treatment of
chronic hepatitis C, a combination of pegylated inter-
feron alfa and ribavirin, sustained virologic response
rates  can  be  achieved  in  approximately  50%  of  pa-
tients only.
Improved understanding of the viral life cycle has
led to the identification of numerous potential targets
for  novel,  direct-acting  antiviral  compounds.  In-
hibitors  of  the  Ns3/4a  protease  are  currently  the
most advanced in clinical development. Recently com-
pleted phase 3 studies of the two protease inhibitors
telaprevir and boceprevir, each given in combination
with  standard  of  care,  yielded  sustained  virologic 
response rates in the range of 66-75% in treatment-
na￯ve patients and 59-66% in treatment-experienced
patients  with  HCv  genotype  1  infection.  studies 
of second-generation protease inhibitors, with the po-
tential advantage of improved potency, drug metabo-
lism and pharmacokinetics profile, are already under-
way. 
Inhibitors  of  the  HCv  Ns5a  protein  and  Ns5B
polymerase are potentially active across different HCv
genotypes and have shown promising antiviral efficacy
in early clinical studies. other emerging mechanisms
include  silymarin  components  and  inhibitors  of  cell
proteins required for HCv replication.
while improved formulations of current HCv ther-
apies are also being developed, future hopes lie on the
combination of direct-acting antivirals with the even-
tual possibility of interferon-free treatment regimens.
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INtRoDUCtIoN
Chronic infection with the hepatitis C virus (HCv) af-
fects  more  than  3%  of  the  world’s  population  [1].
there  are  about  4  million  carriers  in  Europe  alone
who are at risk of developing advanced liver fibrosis,
cirrhosis and hepatocellular carcinoma.
with the current standard of care (soC; pegylated
interferon [PEG-IFN] alfa and ribavirin [RBv]), only
40-50% of patients with HCv genotype 1 infection
and about 80% of patients with HCv genotype 2 or 3
infection can be cured [2-5]. In addition, long treat-
ment  durations  and  therapy-associated  side  effects
such as severe cytopenia, flu-like symptoms or depres-
sion are associated with treatment discontinuation in a
significant number of patients.
Recent advances in the development of HCv cell
culture systems and replication assays have improved
our understanding of the viral life cycle, thus leading
to the identification of numerous potential targets for
novel HCv therapies [6-9]. Indeed, every step of the
HCv life cycle may be used as a therapeutic target.
However, direct-acting antivirals that target post-trans-
lational  processing  of  the  HCv  polyprotein  and  in-
hibitors of the HCv replication complex are currently
the most advanced in clinical development, with stud-
ies ranging from pre-clinical to phase 3. other promis-
ing therapeutic targets include cell proteins that are re-
quired for HCv replication such as cyclophilins. Final-
ly, improvements of current therapies, such as new in-
terferon and ribavirin formulations are also in active
development.
In this review, we will give an overview of recent
advances in HCv drug discoveries with a special em-
phasis on direct-acting antivirals that have progressed
to  phase  2-3  clinical  development  with  anticipated
higher  cure  rates  and  shorter  treatment  durations
compared to standard therapy (table 1). approval of
the first Daas is expected by mid-2011. 
aNtIvIRals taRGEtING HCv PolyPRotEIN
PRoCEssING
Ns3/4a PRotEasE INHIBItoRs
the HCv Ns3/4a protease has been recognized as an
important  target  for  antiviral  therapy  due  to  its  key
role  within  the  HCv  life  cycle  (e.g.  cleavage  of  the
genome-encoded polyprotein and inactivation of cel-
lular proteins required for innate immunity) [6]. 
Inhibitors of the HCv Ns3/4a serine protease are
currently the furthest along in development and they
have shown strong antiviral efficacy but a low genetic
barrier to resistance in early clinical studies. Protease
inhibitors  can  be  divided  into  two  chemical  classes,
macrocyclic inhibitors and linear, tetra-peptide α-ke-
toamide derivates (table 1). 
the clinical proof-of-concept for Ns3/4a protease
inhibitors was achieved with ciluprevir (BIlN 2061), a
macrocyclic protease inhibitor that showed substantial
antiviral activity in patients with HCv genotype 1 [10].
However, ciluprevir was not further developed due to
serious cardiotoxicity observed in a monkey model.
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Table 1. New HCv therapies in the pipeline.
Drug name  Company  Target / Active drug Study phase 
NS3/4A protease inhibitors 
Ciluprevir (BIlN 2061)  Boehringer Ingelheim  active site / macrocyclic  stopped 
Boceprevir (sCH503034) Merck active site / linear Phase 3
telaprevir (vX-950)  vertex  active site / linear  Phase 3 
Danoprevir (RG7227) Roche active site / macrocyclic Phase 2
tMC435 tibotec / Medivir  active site / macrocyclic  Phase 2 
vaniprevir (MK-7009)  Merck  active site / macrocyclic  Phase 2 
BI 201335  Boehringer Ingelheim  active site / linear Phase 2 
BMs-650032 Bristol-Myers squibb active site Phase 2
Gs-9256 Gilead active site Phase 2
aBt-450 abbott / Enanta active site Phase 2
Narlaprevir (sCH900518) Merck active site / linear  on hold
PHX1766 Phenomix active site Phase 1
aCH-1625 achillion active site / linear Phase 2
IDX320 Idenix active site / macrocyclic on hold
MK-5172 Merck active site / macrocyclic Phase 1
vX-985 vertex active site Phase 1
Gs-9451 Gilead active site Phase 1
Nucleos(t)ide NS5B polymerase inhibitors 
valopicitabine (NM-283)  Idenix / Novartis  active site / NM-107 stopped 
RG7128  Roche / Pharmasset  active site / PsI-6130 Phase 2 
IDX184 Idenix active site on hold
R1626  Roche  active site / R1479 stopped 
PsI-7977 Pharmasset active site Phase 2
PsI-938 Pharmasset active site Phase 1
INX-189 Inhibitex active site Phase 1
Non-nucleoside NS5B polymerase inhibitors
BIlB 1941  Boehringer Ingelheim  NNI site 1 / thumb 1 stopped
BI 207127 Boehringer Ingelheim NNI site 1 / thumb 1 Phase 2
MK-3281 Merck NNI site 1 / thumb 1 stopped
Filibuvir (PF-00868554) Pfizer  NNI site 2 / thumb 2 Phase 2
vX-916 vertex NNI site 2 / thumb 2 on hold
vX-222 vertex NNI site 2 / thumb 2 Phase 2
vX-759 vertex NNI site 2 / thumb 2 Phase 1
aNa598  anadys  NNI site 3 / palm 1 Phase 2
aBt-333 abbott NNI site 3 / palm 1 Phase 2
aBt-072 abbott NNI site 3 / palm 1 Phase 2
Nesbuvir (HCv-796)  viroPharma / wyeth  NNI site 4 / palm 2  stopped
tegobuvir (Gs-9190)  Gilead  NNI site 4 / palm 2 Phase 2
IDX375 Idenix NNI site 4 / palm 2 Phase 1
NS5A inhibitors
BMs-790052  Bristol-Myers squibb  Ns5a domain 1 inhibitor Phase 2 
BMs-824393 Bristol-Myers squibb Ns5a inhibitor Phase 1
aZD7295 astraZeneca Ns5a inhibitor Phase 1
PPI-461 Presidio Ns5a inhibitor Phase 1
Indirect inhibitors / unknown mechanism of action
NIM811 Novartis Cyclophilin inhibitor stopped 
sCy-635 scynexis Cyclophilin inhibitor Phase 1 
alisporivir (Debio-025)  Debiopharm / Novartis Cyclophilin inhibitor Phase 2
alinia (nitazoxanide)  Romark PKR induction ? Phase 2 
Celgosivir  Biowest alpha-glucosidase inhibitor stopped 
New formulations of current therapies
taribavirin valeant / ribavirin Phase 2
locteron (BlX-883) Biolex Interferon receptor type 1 Phase 2
PEG-rIl-29 (peginterferon lambda) ZymoGenetics / BMs Interferon receptor type 3 Phase 2
Joulferon (albinterferon alfa-2b) HGs / Novartis interferon receptor type 1 stopped
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telaprevir (vX-950), an orally bioavailable, linear, ke-
toamide  protease  inhibitor,  was  initially  investigated
given alone or in combination with PEG-IFN alfa-2a
ﾱ RBv in patients infected with HCv genotype 1 in a
number of short-term studies [11-13]. a median maxi-
mum reduction of -5.49 log10 IU/ml HCv RNa from
baseline was observed in patients treated with telapre-
vir (750 mg three times daily) plus PEG-IFN alfa for
14 days. Mutations associated with clinical resistance
to telaprevir were identified at 4 positions close to the
Ns3  catalytic  domain  -  v36a/M/l,  t54a,
R155K/M/s/t, a156s (all three conferring low- to
medium-level  resistance)  and  a156t/v  (conferring
high-level resistance) [14, 15]. viral rebound due to se-
lected drug-resistant mutants occurred in the majority
of patients during monotherapy with telaprevir. How-
ever, a reduced frequency of resistant mutations and
no viral breakthrough was observed in the combina-
tion studies.
subsequently,  the  efficacy  of  telaprevir  (750  mg
three times daily) in combination with PEG-IFN 2a ﾱ
RBv  was  studied  in  three  large  placebo-controlled
phase 2b trials in both treatment-na￯ve (PRovE 1, n=
250;  PRovE  2,  n=  323)  and  treatment-experienced
(PRovE  3,  n=  453  patients  with  HCv  genotype  1
[16-18].  overall,  svR  rates  ranged  from  67-69%
(PRovE 1/2) and 24-53% (PRovE 3) in the telapre-
vir containing study arms compared to 41-46% and
14% in patients receiving soC, respectively. lower an-
tiviral activities, higher break-through and high relapse
rates (48% and 53%, respectively) were observed in
the RBv-free study arms, indicating that RBv remains
crucial for the achievement of sustained virologic re-
sponse.  Finally,  discontinuation  rates  due  to  adverse
events, including severe skin rashes, increased to near-
ly  26%  in  patients  who  received  telaprevir  for  24
weeks. thus, in subsequent studies, telaprevir dosing
was restricted to a maximum of 12 weeks. In a smaller,
open-label study of telaprevir plus soC in treatment-
na￯ve patients with HCv genotype 1, equally high svR
rates for telaprevir administered every 12 hours vs. 8
hours and given in combination with PEG-IFN alfa-
2a/RBv  vs.  PEG-IFN  alfa-2b/RBv  were  observed
[19].
telaprevir  was  also  investigated  in  patients  with
HCv genotype 2, 3 and 4. while a slightly reduced an-
tiviral activity was observed in patients with genotype
2 infection, only minimal declines of HCv RNa con-
centrations  were  observed  in  patients  infected  with
HCv genotypes 3 and 4 [20, 21].
three  landmark  phase  3  trials,  known  as  aD-
vaNCE  (n=  1088),  IllUMINatE  (n=  540),  both
conducted in treatment-na￯ve patients, and REalIZE
(n=  662),  conducted  in  treatment-experienced  pa-
tients,  evaluated  the  efficacy  of  telaprevir  (750  mg
three times daily) in combination with soC for 24-48
weeks  and  48  weeks  overall  treatment  duration,  re-
spectively, in patients with HCv genotype 1 infection
[22-24] (Fig. 1a/B). 
the aDvaNCE study had three study arms - 12
weeks of telaprevir plus soC followed by soC alone
for 12 or 36 weeks, 8 weeks of telaprevir plus soC
followed by soC alone for 16 or 40 weeks and soC
alone for 48 weeks. as part of a response-guided de-
sign,  patients  in  the  telaprevir-based  treatment  arms
who had undetectable HCv RNa at week 4 and week
12 of treatment (eRvR, extended rapid virologic re-
sponse) were eligible to receive 24 total weeks of ther-
apy. Patients who did not meet this criterion but had
undetectable HCv RNa at week 24 received 48 total
weeks of therapy. the overall svR rates ranged from
69% in patients who received 8 weeks of telaprevir to
75% in patients who received telaprevir for 12 weeks,
compared to 44% in patients who received soC alone.
Nearly 60% (57% and 58%, respectively) of patients
in the telaprevir-based study arms were eligible to un-
dergo  shortened  treatment  duration.  Relapse  rates
were 9%, 9% and 28%, respectively. treatment discon-
tinuation due to drug-related adverse events during the
first 12 weeks of overall treatment occurred in 8%,
7% and 4% of patients, respectively. 
the  IllUMINatE  trial  was  conducted  in  treat-
ment-na￯ve  patients  to  investigate  the  benefit  of
longer treatment duration in patients who achieved an
eRvR (65%) following 12 weeks of telaprevir-based
therapy. In this study, svR rates were 92% in eRvR
patients who received 24 total weeks of therapy com-
pared to 88% in eRvR patients on 48 total weeks of
treatment. 
taken together, eRvR was identified as a key pre-
dictor of svR and the majority of patients were eligi-
ble  to  undergo  shortened  treatment  duration  with
equally high svR rates compared to the standard ther-
apy duration of 48 weeks.
the REalIZE study evaluated the efficacy of a 12-
week triple combination treatment regimen followed
by 36 weeks soC or 4-week lead-in with soC, fol-
lowed  by  12  weeks  triple  combination  therapy,  fol-
lowed by 32 weeks of soC in treatment-experienced
patients  with  HCv  genotype  1  (partial  non-respon-
ders,  ≥2  log10 decline  but  detectable  HCv  RNa  at
treatment-week 12; null-responders, <2 log10 decline
in HCv RNa at week 12; and relapsers) vs. soC alone
for 48 weeks. svR rates for the three treatment arms
were 64%, 66% and 17%, respectively. Prior relapsers
achieved svR rates of 83%-88%, while prior null re-
sponders  achieved  svR  rates  in  the  range  of  29%-
33%. a response-guided treatment-arm with shorten-
ing  of  treatment  duration  was  not  included  in  this
study. Discontinuation due to adverse events occurred
in 4% of the combined telaprevir study arms and in
3% of the control group. the relatively low discontin-
uation rates due to adverse events in all three phase 3
studies may be explained by precise management plans
for telaprevir-induced rashes that involved expert der-
matologist consultations at each study site. 
During triple therapy with telaprevir plus PEG-IFN
alfa/RBv, viral breakthrough associated with the selec-
tion of resistant variants was observed in 1-5% of treat-
ment-na￯ve patients and in up to 25% of previous non-
responders. Moreover, variants conferring resistance to
Ns3 protease inhibitors were also detected in patients
with viral relapse after the end of treatment. the long-
term  significance  of  these  resistant  variants  is  un-
known but generally a decline in frequency over time
has  been  observed  [25].  However,  in  single  patients,
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observed up to 4 years after telaprevir therapy [26].
BoCEPREvIR
In  a  phase  1b  study  conducted  in  treatment-experi-
enced patients with HCv genotype 1, administration
of boceprevir (200 mg or 400 mg three times daily), a
peptidomimetic α-ketoamide HCv protease inhibitor,
with  or  without  PEG-IFN  alfa-2b  resulted  in  mean
maximum  reductions  of  HCv  RNa  of  up  to  1.61
log10 and 2.88 log10 IU/ml, respectively [27]. subse-
quently, a number of mutations conferring boceprevir
resistance at low to medium levels were discovered in
vivo  -  v36M/a,  t54a/s,  v55a,  R155K/t,  a156s,
and v170a [28, 29].
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Fig. 1A/B. 
a) aDvaNCE and IllUMINatE were conducted in treatment-na￯ve patients with HCv genotype 1. the aDvaNCE treat-
ment arms were as follows: (i) 12 weeks of telaprevir (t) plus PEG-IFN alfa-2a and ribavirin (PR) followed by PR for 12 or 36
weeks, based on treatment response at week 4 and 12, (ii) 8 weeks of t plus PR followed by PR for 16 or 40 weeks, based on
treatment response at week 4 and 12; (iii) PR alone for 48 weeks. In the IllUMINatE trial, patients who achieved an eRvR
were randomized to receive 12 weeks of t plus PR followed by PR for (i) 12 weeks or (ii) 24 weeks. 
B) treatment-experienced patients with HCv genotype 1 (REalIZE) received (i) 12 weeks of t plus PR followed by PR for 36
weeks, (ii) 4 weeks PR lead-in followed by tPR for 12 weeks followed by PR alone for 32 weeks (iii) PR alone for 48 weeks. In
the REalIZE study, relapsers and non-responder (null-responders and partial non-responders) patients were enrolled.
*eRvR defined as HCv RNa negativity at week 4 and 12.
Fig. 2A/B.
a) sPRINt-2 treatment arms in treatment-na￯ve patients with HCv genotype 1 were as follows: (i) 4-week lead-in with PEG-
IFN alfa-2b plus ribavirin (PR) followed by 44 weeks of PR plus boceprevir (B); (ii) 4-week lead-in with PR followed by PR plus
B for 24 weeks or followed by PR plus B for 24 weeks and PR for additional 20 weeks, based on treatment response at week 8
and 12; (iii) PR alone for 48 weeks. 
B) the REsPoND-2 treatment schedule, conducted in treatment-experienced patients with HCv genotype 1 was as follows: (i)
4-week lead-in with PR followed by PR plus B for 44 weeks, (ii) 4-week lead in with PR followed by PR plus B for 32 weeks or
followed by PR plus B for 32 weeks and PR for additional 12 weeks, based on treatment response at week 8 and 12; (iii) PR
alone for 48 weeks.
**eRvR defined as HCv RNa negativity at week 8 through 24; ***in the sRINt-2 control arm, only standard RvR data (nega-
tive HCv RNa at week 8) are shown. ERvR results were not available at the time of submission of this manuscript.
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ceprevir in HCv genotype 2/3 infected patients were
reported. 
a higher dose of boceprevir (800 mg three times
daily) in combination with PEG-IFN alfa-2b and RBv
was subsequently tested in a larger, phase 2 clinical tri-
al  (sPRINt-1;  n=  595)  in  treatment-na￯ve  patients
with HCv genotype 1 infection [30]. Patients received
either  all  three  drugs  in  combination  for  28  or  48
weeks or for 24 or 44 weeks after a previous 4-week
lead-in period of PEG-IFN alfa-2b/RBv, or soC for
48 weeks. svR rates ranged from 54% for 28 weeks of
triple  therapy  to  75%  after  a  4-week  lead-in  period
with PEG-IFN alfa-2b/RBv followed by 44 weeks of
triple therapy compared to 38% in the control group.
treatment  discontinuations  due  to  adverse  events
(mainly anaemia and gastro-intestinal side effects) that
occurred throughout the entire study appeared in 9%-
19% of patients receiving boceprevir compared to 8%
in the control group. 
In patients with prior non-response to soC thera-
py, the addition of boceprevir to PEG-IFN alfa and
RBv showed only slightly increased svR rates com-
pared to standard therapy in a phase 2b study with
suboptimal  boceprevir/RBv  dosing  (14%  vs.  2%)
[31]. 
the delayed start of boceprevir by four weeks, dur-
ing which time patients received four weeks of soC
alone (lead-in), was designed to decrease the probabili-
ty of resistance development. among patients with a
null-response to the 4-week lead-in treatment period
(<1.0  log10 IU/ml  HCv  RNa  reduction),  the  svR
rate was 25% for patients who continued 24 weeks of
triple  therapy  and  55%  for  those  who  received  44
weeks of triple therapy. In contrast, patients who had
a >2log10 IU/ml decline in HCv RNa achieved svR
rates of 73-81%. thus, virologic response to the lead-
in allows for prediction of subsequent treatment suc-
cess. However, even in lead-in-null-responders a sig-
nificant  improvement  in  svR  rates  following  subse-
quent triple therapy was observed.
In two phase 3 studies, a larger number of treat-
ment-na￯ve (sPRINt-2; n= 1097) and treatment-ex-
perienced (REsPoND-2; n= 403; partial non-respon-
ders and relapsers only) patients with HCv genotype
1 infection were enrolled to receive a 4-week lead-in
with PEG-IFN alfa-2b/RBv alone, followed by either
44 weeks of triple combination therapy or a response-
guided schedule with the possibility of stopping ther-
apy at week 28 or week 36 of overall treatment dura-
tion (based on eRvR, defined as HCv RNa negative
at week 8 and week 24), respectively [32, 33]. among
treatment-na￯ve  patients,  66%  in  the  48-week  treat-
ment group and 63% in the response-guided therapy
group achieved svR compared to 38% in the control
group. In treatment-experienced patients, 66% in the
48-week treatment group and 59% in the response-
guided therapy group achieved svR compared to 21%
in the control group. overall, 44% of patients in the
sPRINt-2 response-guided treatment arm and 46%
of  patients  in  the  REsPoND-2  response-guided
treatment  arm  were  eligible  to  undergo  shortened
treatment  durations,  based  on  eRvR  results. 
treatment discontinuations due to adverse events oc-
curred in 12-16% of treatment-na￯ve patients and 8-
12% of treatment-experienced patients, compared to
16% and 3% in the control groups, respectively (Fig.
2a/B). 
otHER PRotEasE INHIBItoRs
a number of second-generation Ns3/4a protease in-
hibitors  are  currently  in  early  clinical  development.
among  these,  danoprevir  (RG7227),  tMC435,  va-
niprevir  (MK-7009),  BI201335,  narlaprevir
(sCH900518),  BMs-650032,  PHX1766;  aCH-1625,
aBt-450, MK-5172, Gs-9256, and Gs-9451 have all
been tested in phase 1 and/or phase 2 clinical trials
[34-46]. overall, these compounds exhibit a high an-
tiviral activity in HCv genotype 1 patients and recently
reported phase 2 results were comparable to, or even
surpassed  svR  results  obtained  with  telaprevir  and
boceprevir [34, 39, 44]. 
Potential  advantages  of  these  second-generation
protease inhibitors include improved pharmacokinet-
ics (one to two times daily dosing), broader genotypic
activity, coverage of first generation protease inhibitor
resistance  mutations  and  better  tolerability.  In  addi-
tion, ritonavir boosting is being investigated in a num-
ber of protease inhibitors, including narlaprevir and
danoprevir, to reduce side effects and to enhance pa-
tient exposure to the latter agents, thereby potentially
overcoming  resistance  issues  and  allowing  less  fre-
quent dosing.
overlapping resistance profiles have been reported
for  all  Ns3  protease  inhibitors  that  are  currently  in
phase 2-3 development [47].
aNtIvIRals taRGEtING tHE HCv RNa
PolyMERasE
Ns5B PolyMERasE INHIBItoRs
the active site of the HCv Ns5B polymerase repre-
sents an interesting target for anti-HCv therapies as it
forms  a  highly  conserved  structure  across  all  HCv
genotypes [48]. Currently, two classes of Ns5B poly-
merase inhibitors can be distinguished - nucleoside or
nucleotide analogue inhibitors that mimic the natural
substrates  of  the  RNa-dependent  RNa-polymerase
and are incorporated at the active site of the enzyme
into the elongated RNa where they act as chain termi-
nators, and non-nucleoside analogue inhibitors, repre-
senting  a  heterogeneous  group  of  antiviral  com-
pounds that bind to different allosteric enzyme sites,
resulting  in  a  conformational  protein  change  before
the elongation complex is formed (table 1). 
NUClEos(t)IDE INHIBItoRs
Nucleos(t)ide  polymerase  inhibitors  target  the  active
binding site of Ns5B, with potential activity against all
HCv genotypes. Despite promising results from early
clinical studies, further development of the first two
nucleoside  polymerase  inhibitors,  valopicitabine  and
R1626,  was  halted  due  insufficient  antiviral  activity
and severe adverse events [49-51].
RG7128, a prodrug of the cytidine nucleoside ana-
logue PsI-6130, is currently under investigation in an
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ment-na￯ve patients with HCv genotype 1 or 4 (n=
408). Interim results on complete early virologic re-
sponse  (cEvR;  negative  HCv  RNa  at  week  12)
showed up to 87% HCv RNa negativity for patients
who received RG7128 at a dose of 1000 mg twice dai-
ly for 12 weeks plus soC and no resistance related vi-
ral breakthrough was reported [52]. 
PsI-7977, a chirally pure isomer form of PsI-7851,
has yielded promising early data with high RvR rates
(88-94%)  across  different  dose  groups  plus  soC  in
treatment-na￯ve  patients  with  HCv  genotype  1  [53].
the nucleotide analogue PsI-938 is still in the early
stages of clinical development [54].
NoN-NUClEosIDE INHIBItoRs
the  structure  of  the  Ns5B  polymerase  resembles  a
characteristic “right hand motif”, consisting of finger,
palm  and  thumb  domains.  at  least  4  different  al-
losteric binding sites have been identified for the inhi-
bition of the Ns5B polymerase by non-nucleoside in-
hibitors - (i) a benzimidazole (thumb 1)-, (ii) a thio-
phene (thumb 2)-, (iii) a benzothiadiazine (palm 1)-,
and (iv) a benzofuran (palm 2)-binding site [47]. as
non-nucleoside inhibitors bind more distantly to the
active site of Ns5B, resistant mutations occur more
frequently in these compounds.
(i) Non-nucleoside site 1 inhibitors 
(thumb 1 / benzimidazole site)
BI 207127, BIlB1941, and MK-3281 are non-nucleo-
side-site 1 inhibitors that have been shown to exhibit
low to medium antiviral activity in phase 1 clinical tri-
als [55-57]. Four weeks of BI 207127 (600 mg three
times  daily)  in  combination  with  PEG-IFN  alfa-
2a/RBv  has  resulted  in  a  median  reduction  of  5.6
log10 HCv  RNa  in  treatment-na￯ve  genotype  1  pa-
tients  and  no  viral  breakthrough  was  observed  [58].
Results of further studies have to be awaited. the fur-
ther  development  of  BIlB1941  and  MK-3281  was
halted due to gastrointestinal adverse events.
(ii) Non-nucleoside site 2 inhibitors 
(thumb 2 / thiophene site)
Interim results from a phase 1 trial investigating differ-
ent doses of filibuvir (PF-00868554), a non-nucleoside
site 2 inhibitor, in combination with soC for 4 weeks
followed  by  soC  for  44  weeks  have  shown  similar
svR (at 12 weeks follow-up) results for the different
filibuvir groups compared to the soC group, indicat-
ing that longer dosing of filibuvir may be necessary
[59]. other site 2-inhibitors include vX-759, vX-916,
and vX-222 [60-62]. However, at this point, only vX-
222 has progressed to phase 2 developments.
(iii) Non-nucleoside site 3 inhibitors 
(palm 1 / benzothiadiazine site)
a phase 2 trial of aNa598 in combination with PEG-
IFN  alfa-2a/RBv  in  treatment-na￯ve  patients  with
HCv genotype 1 is currently ongoing. It was recently
reported that 75% of patients who received 400 mg of
aNa598 twice daily achieved undetectable HCv RNa
levels at treatment week 12 [63]. other site 3-palm 1-
inhibitors  include  aBt-072  and  aBt-333,  both  of
which have entered phase 2 clinical trials [64]. 
(iv) Non-nucleoside site 4 inhibitors 
(palm 2 / benzofuran site)
Monotherapy  with  HCv-796  (nesbuvir)  showed  low
antiviral activity in patients with HCv genotype 1. In
addition,  selection  of  resistant  variants  and  viral
breakthrough  was  observed  in  several  patients  [65].
Further drug development was suspended due to ab-
normal liver enzyme elevations in a subsequent phase
2  study.  Gs-9190  (tegobuvir)  displayed  low  antiviral
activity in a phase 1 clinical study and drug-resistant
variants  were  observed.  However,  Gs-9190  has  en-
tered phase 2 clinical trials, both in combination with
soC and with the protease inhibitor Gs-9256 ﾱ RBv
[66]. Finally, IDX375 also binds to the palm pocket
and is currently in phase 1 clinical trials [67].
Ns5a INHIBItoRs
Inhibitors of Ns5a are potentially active against all
HCv genotypes. BMs-790052 binds to domain I of
the Ns5a protein, which is crucial for the regulation
of HCv replication, assembly and release. Following
the promising results from a phase 1 study [68], BMs-
790052 is currently under investigation in a number of
phase 2 clinical trials. Recently, interim data were re-
leased  from  a  phase  2  study  investigating  different
doses of BMs-790052 in combination with soC. RvR
rates were 83% and 92% in patients who received 10
mg and 60 mg BMs-790052 once daily, respectively. In
addition,  undetectable  HCv  RNa  levels  at  week  12
(cEvR) were observed in 83% of patients [69]. other
Ns5a inhibitors include BMs-824393, aZD7295, and
PPI-461 [70-72].
Daa CoMBINatIoN tHERaPIEs
treatment discontinuation rates due to interferon-as-
sociated side effects are commonly observed, especial-
ly in the routine daily practice [73]. therefore, one of
the primary future goals of Daa therapy is to control
viral replication or even to achieve svR in interferon-
free regimens. In the placebo-controlled INFoRM-1
study,  combinations  of  different  doses  of  a  poly-
merase inhibitor (RG7128) and a Ns3/4a protease in-
hibitor (danoprevir) were tested in 87 treatment-na￯ve
and -experienced patients with HCv genotype 1 for
up to 2 weeks [74]. at the highest doses tested (1000
mg RG7128 and 900 mg danoprevir twice daily), 63%
of treatment-na￯ve patients and 25% of treatment-ex-
perienced patients achieved undetectable HCv RNa
after 2 weeks of combination therapy and only one
patient experienced viral rebound without exhibiting
resistant mutations. 
several other drug combinations are actively being
investigated. In a phase 2 study of the Ns3 protease
inhibitor Gs-9256 (75 mg twice daily) plus the non-
nucleoside Ns5B polymerase inhibitor tegobuvir (40
mg twice daily) alone or in combination with RBv or
PEG-IFN  alfa/RBv  for  up  to  28  days,  viral  break-
through was observed for the combination of the two
direct  antiviral  compounds  only.  this  clearly  shows
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sufficient for continuous suppression of virus replica-
tion. Interestingly, the addition of RBv enhanced an-
tiviral  activity  and  reduced  viral  breakthrough  rates,
even in the absence of PEG-IFN alfa [75]. 
an  IFN-sparing  triple  combination  therapy  with
the Ns3 protease inhibitor BI 201335 (12mg once dai-
ly)  and  the  non-nucleoside  polymerase  inhibitor  BI
207127  (400  mg  or  600  mg  three  times  daily)  plus
RBv resulted in residual or even undetectable HCv
RNa levels after 4 weeks in all patients treated with
the higher dose of BI 207127 [76]. 
Finally,  in  an  ongoing  trial  of  HCv  genotype  1
null-responders  treated  with  the  Ns5a  inhibitor
BMs-790052 plus the Ns3 protease inhibitor BMs-
650032  alone  or  in  combination  with  PEG-IFN
alfa/RBv  for  24  weeks,  5/11  and  9/10  patients
achieved  cEvR,  respectively.  all  patients  with  viral
breakthrough in the Daa-only combination regimen
(6/11) were genotype 1a patients. this important ob-
servation indicates that different antiviral activities of
Daas may be present on the HCv subtype level [77].
an overview of current combination therapy trials is
given in table 2.
overcoming  drug  resistance  will  be  the  primary
challenge  in  Daa  combination  therapies  and
nucleos(t)ide analogues with a high genetic barrier to
resistance and/or drug combinations that have a ge-
netic barrier of four or more mutations may be re-
quired [78] (see table 3). Future trials need to address
the tolerability and safety of long-term Daa adminis-
tration and whether svR can be achieved without the
addition of PEG-IFN alfa/RBv.  
EMERGING MECHaNIsMs
CyCloPHIlIN INHIBItoRs
Cyclophilins  are  ubiquitous  proteins  in  human  cells
that  are  involved  in  protein  folding.  Moreover,  cy-
clophilins participate in HCv replication as functional
regulators of the HCv Ns5B polymerase.
the cyclophilin inhibitor Debio-025 (alisporivir), a
cyclosporine a analogue, showed antiviral activity in
patients infected with different HCv genotypes (1–4)
during monotherapy and in combination studies with
PEG-IFN alfa. Maximum log10 changes in HCv RNa
of up to 4.75 were observed in patients with HCv
genotypes 1 or 4 who received 1000 mg Debio-025 in
combination with PEG-IFN alfa-2a/RBv for 4 weeks
[79]. Interestingly, there is even one case report of a
genotype  3a  patient  who  achieved  svR  following  4
weeks  of  Debio-025  1000  mg/day  as  monotherapy
[80]. Despite the selection of HCv variants with mu-
tations clustering in the Ns5a gene that showed resis-
tance to Debio-025 in the HCv replicon system [81],
no  viral  breakthrough  has  been  observed  in  clinical
studies so far.
sCy-635  is  another  non-immunosuppressive  ana-
logue of cyclosporine a that exhibits potent suppres-
sion of HCv. Different doses of sCy-635 were inves-
tigated in patients infected with HCv genotype 1 and
a mean maximum decline of 2.3 log10 IU/ml in viral
load was observed after 15 days of 900 mg sCy-635
monotherapy  [82].  No  viral  rebound  was  observed
during sCy-635 therapy. However, minimal evidence
of  resistance  selection  was  observed  within  Ns5B
[83]. 
sIlIBININ
silymarin,  an  extract  of  milk  thistle  (Silybum  mari-
anum) with antioxidant activity has been used as self-
medication for liver diseases over centuries [84]. silib-
inin  is  one  of  the  six  major  ﬂavonolignans  in  sily-
marin. though its mechanism of action and treatment
efficacy is not yet fully understood, it was recently re-
ported that silibinin is a direct inhibitor of the Ns5B
polymerase [85]. other findings suggest that silymarin
blocks virus entry and transmission, possibly by tar-
geting the host cell [86].
Intravenous silibinin was investigated in 36 non-re-
sponders  to  prior  PEG-IFN-based  antiviral  therapy
and showed a significant decline in HCv RNa (0.55
to  3.02  log10 IU/ml)  after  7  days  and  a  further  de-
crease  after  additional  7  days  in  combination  with
PEG-IFN alfa-2a/RBv in the range of 1.63 to 4.85
log10 IU/ml. HCv RNa became undetectable in 7 pa-
tients on 15 or 20 mg/kg silibinin at week 12 of total
treatment [87]. Recently, it was reported that a short
course  of  intravenous  silibinin  (2  days  of  1400mg)
could be used as a rescue approach in patients show-
ing non-response to soC [88]. studies in larger patient
cohorts including resistance analyses are underway.
NEw FoRMUlatIoNs oF CURRENt tHERaPIEs
RIBavIRIN aNaloGUEs
adverse haematological effects associated with RBv
are commonly observed and have prompted the devel-
opment of taribavirin, a prodrug that is converted to
RBv and is concentrated in the liver, leading to re-
duced RBv uptake by red blood cells. In two phase 3
trials, administration of taribavirin (600 mg twice dai-
ly) plus PEG-IFN alfa-2a or -2b failed to achieve non-
inferiority  to  administration  of  weight-based  RBv
plus PEG-IFN alfa-2a/b [89, 90]. In a recently com-
pleted  phase  2b  trial,  weight-based  taribavirin  was
non-inferior  compared  to  weight-based  RBv,  with
fewer  haematological  side  effects  [91].  However,
anaemia rates increased with higher taribavirin dosing
and the dropout rates for anaemia did not differ be-
tween the two study drugs. therefore, the future role
of taribavirin remains to be elucidated.
NEw INtERFERoNs
albinterferon  alfa-2b  (Joulferon)  is  a  recombinant
protein consisting of interferon alfa-2b fused to hu-
man  albumin  that  can  be  administered  every  two 
or four weeks due to a longer half-life compared to
the  currently  marketed  pegylated  interferons.  How  -
ever, albinterferon was neither better tolerated nor did
it show superior efficacy in patients with HCv geno-
type 1 or 2/3 in two large phase 3 studies [92, 93].
owing to concerns expressed by the regulatory au-
thorities  regarding  the  drug’s  benefit/risk  ratio,  the
approval  process  of  albinterferon  was  recently  sus-
pended. 
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terferon  alfa-2b  that  can  be  administered  every  two
weeks. week 12 interim results from a phase 2b study
have shown a similar reduction in HCv RNa and a re-
duction of flu-like symptoms by 57% for locteron at a
dose  of  480  ﾵg  compared  to  PEG-IFN  alfa-2b  in
treatment-na￯ve  patient  with  HCv  genotype  1  [94].
svR results have not yet been reported. 
a non-pegylated, type I interferon alpha-formula-
tion, consensus interferon, has recently been approved
in combination with ribavirin for non-responders to
PEG-IFN  therapy  [95].  Finally,  PEG-IFN  lambda
(PEG-rIl-29) is a type III interferon that binds to a
unique  receptor  with  more  limited  distribution  than
the type I interferon receptor used by interferon alpha.
In a phase 1b trial, 56 treatment-na￯ve patients and pa-
tients who relapsed after soC were enrolled to receive
different  doses  of  PEG-IFN  lambda  (ranging  from
0.5  to  3.0  ﾵg/kg)  administered  every  two  weeks  or
weekly with or without daily RBv for four weeks. an-
tiviral activity was seen at all dose levels with a mean
maximum  change  of  HCv  RNa  from  baseline  of
3.27 log10 IU/ml in treatment na￯ve patients treated
with weekly PEG-IFN lambda (1.5ﾵg/kg) plus RBv
[96]. In addition, minimal flu-like symptoms and no
significant haematological side effects were observed.
Phase 2 trials are currently ongoing.
CoNClUsIoNs
while treatment success in patients with HCv geno-
type 1, the most prevalent genotype in Europe and the
Usa, remains suboptimal with the current standard of
care,  a  number  of  promising  direct-acting  antiviral
compounds offer new hope for a cure.
Recently completed pivotal phase 3 studies of the
currently most advanced Ns3/4a protease inhibitors,
telaprevir  and  boceprevir,  have  shown  svR  rates  in
the  range  of  69-75%  and  63-66%,  respectively,  in
treatment-na￯ve patients with HCv genotype 1 infec-
tion.  additional  important  findings  include  the  suc-
cessful application of shortened treatment durations
of 24/28 weeks in 50-65% of patients, based on ex-
tended rapid on-treatment response. Finally, patients
who failed a prior course of interferon-based therapy
may also be successfully cured, with svR rates of 64-
66% and 59-66% in telaprevir- and boceprevir-based
regimens, respectively. No protease inhibitor head-to-
head studies have been conducted so far.
Nucleos(t)ide and non-nucleoside inhibitors of the
HCv Ns5B polymerase have shown promising antivi-
ral efficacy in early clinical studies. Unlike protease in-
hibitors, which are mostly active in patients with HCv
genotype  1  only,  nucleos(t)ide  polymerase  inhibitors
bind to the highly conserved centre of the HCv poly-
merase, with the potential advantage of equal effec-
tiveness in different HCv genotypes. However, svR
results from larger studies have to be awaited.
at present, a number of studies focus on different
combinations  of  different  HCv  protease  and  poly-
merase  inhibitors  with  or  without  the  addition  of
soC.  while  a  rapid  and  profound  decline  in  HCv
RNa was observed in most of these studies, sustained
virologic response may be only achieved with combi-
nation therapies using at least 3 compounds or with
PEG-IFN/RBv  as  a  therapeutic  backbone  for  the
foreseeable future.
while HCv protease and polymerase inhibitors are
likely to take the lead in future anti-HCv drug regi-
mens, there are a number of additional therapeutic ap-
proaches that may eventually find their place within
the HCv armamentarium. among these, inhibitors of
the  non-structural  protein  5a  and  cyclophilin  in-
hibitors are currently the furthest along in the pipeline.
with the addition of new antiviral compounds to
standard therapy, a number of additional side effects
unrelated to soC have been observed, and increased
treatment-discontinuation  rates  have  been  reported.
Consequently,  successful  management  of  these  side
effects will gain in importance and will have increasing
influence  on  treatment  outcomes.  In  addition,  fre-
quent dosing intervals (i.e. three times daily) may lead
to  increased  non-adherence  outside  of  clinical  trials
and more patient-friendly formulations have to be de-
veloped.
one of the major challenges of future anti-HCv
treatment regimens will be the emerging field of Daa
drug resistance. Relatively low genetic barriers to resis-
tance have been reported for HCv protease inhibitors
and  non-nucleoside  polymerase  inhibitors  as  com-
pared to nucleos(t)ide HCv polymerase inhibitors that
appear  to  have  a  high  genetic  barrier  to  resistance.
However, HCv eradication may not be achieved with
monotherapy from either substance group and drug
combinations with non-cross-resistance patterns have
to be further evaluated. In addition, pre-existing resis-
tant variants and their potential long-term persistence
have to be taken into account for the selection of op-
timal treatment and re-treatment strategies. Finally, the
potential risks of drug-drug interactions, especially in
patients with HIv co-infection who are on antiretrovi-
ral therapy, will likely gain in importance, while num-
bers  of  patients  treated  with  Daas  are  increasing.
therapeutic drug monitoring may eventually play an
important role in the management of these interac-
tions [97].
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